SGLT2 Inhibitors Linked to Reduced Sepsis-Related Cardiomyopathy in T2D Patients

Overview

This retrospective cohort study using the TriNetX database found that baseline use of SGLT2 inhibitors in patients with type 2 diabetes and sepsis was associated with a lower incidence of sepsis-induced cardiomyopathy compared to DPP4 inhibitors. Propensity score matching ensured balanced baseline characteristics between groups, strengthening the observed association.

Background

Sepsis can cause multi-organ dysfunction, with cardiovascular complications such as sepsis-induced cardiomyopathy (SICM) occurring in up to 50% of cases. SICM is characterized by transient myocardial dysfunction and is linked to increased short-term mortality. Type 2 diabetes mellitus (T2D) predisposes patients to heightened inflammatory responses, potentially increasing SICM risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2is) have demonstrated cardiovascular benefits in heart failure beyond glycemic control, suggesting potential protective effects against SICM in septic patients with T2D.

Data Highlights

Key Findings

• Baseline use of SGLT2 inhibitors was associated with a significantly lower risk of developing sepsis-induced cardiomyopathy compared to DPP4 inhibitors in patients with T2D and sepsis.
• Propensity score matching balanced demographic, clinical, and medication variables between groups, minimizing confounding.
• The primary outcome observation window was 30 days post-infection, focusing on early SICM incidence.
• Secondary outcomes including all-cause mortality, hospitalization, and MACEs were evaluated over a 365-day period.
• SGLT2 inhibitors’ cardioprotective effects may extend to preventing myocardial dysfunction in the setting of sepsis beyond their known benefits in heart failure.

Clinical Implications

Clinicians managing patients with type 2 diabetes who develop sepsis might consider the potential cardioprotective benefits of SGLT2 inhibitors in reducing the risk of sepsis-induced cardiomyopathy. Given the association observed, SGLT2is could be favored over DPP4is in appropriate patients to mitigate cardiovascular complications during sepsis. Further prospective studies are warranted to confirm these findings and guide clinical decision-making.

Conclusion

This real-world analysis suggests that SGLT2 inhibitor therapy is linked to a reduced incidence of sepsis-related cardiomyopathy in patients with type 2 diabetes. These findings highlight a potential preventive role for SGLT2is in mitigating cardiovascular dysfunction during sepsis.

References

1. Introduction and Methods Sections -- Link Between SGLT2 Inhibitor Administration and the Incidence of Sepsis-Related Cardiomyopathy in Individuals with Type 2 Diabetes: A Propensity-Matched Analysis